Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03410979
Recruitment Status : Completed
First Posted : January 25, 2018
Last Update Posted : January 25, 2018
Sponsor:
Information provided by (Responsible Party):
Galapagos NV

Brief Summary:
This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days.

Condition or disease Intervention/treatment Phase
Healthy Drug: GLPG2737 single dose Drug: Placebo single dose Drug: GLPG2737 multiple dose Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 79 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A 2-part, Randomized, Double-blind, Placebo-controlled, Sequential Group, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2737 in Healthy Male Subjects
Actual Study Start Date : November 25, 2016
Actual Primary Completion Date : August 15, 2017
Actual Study Completion Date : August 15, 2017

Arm Intervention/treatment
Experimental: GLPG2737 single dose
Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order
Drug: GLPG2737 single dose
GLPG2737 oral suspension, single ascending doses

Placebo Comparator: Placebo single dose
Single doses of Placebo oral suspension
Drug: Placebo single dose
Placebo, oral suspension.

Experimental: GLP2737 multiple dose
Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order
Drug: GLPG2737 multiple dose
GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.

Placebo Comparator: GLPG2737 multiple dose
Multiple doses of Placebo oral suspension
Drug: GLPG2737 multiple dose
Placebo, oral suspension, daily for 14 days




Primary Outcome Measures :
  1. Change versus placebo in the proportion of subjects with adverse events [ Time Frame: Between screening and 14 days (SAD part) and 15 days (MAD part) after the last dose ]
    To assess safety and tolerability of single and multiple ascending doses with GLPG2737 versus placebo in healthy subjects.


Secondary Outcome Measures :
  1. Maximum observed plasma concentration (Cmax) of GLPG2737 [ Time Frame: Between Day 1 predose and 5 days after the last dose ]
    To characterize pharmacokinetics of GLPG2737 and its metabolites after single and multiple oral doses in healthy subjects

  2. Time of occurrence of Cmax for GLPG2737 (tmax) [ Time Frame: Between Day 1 predose and 5 days after the last dose ]
    To characterize pharmacokinetics of GLPG2737 and its metabolites after single and multiple oral doses in healthy subjects

  3. Area under the plasma concentration-time curve (AUC0-t) of GLPG2737 [ Time Frame: Between Day 1 predose and 5 days after the last dose ]
    To characterize pharmacokinetics of GLPG2737 and its metabolites after single and multiple oral doses in healthy subjects

  4. Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects [ Time Frame: Day 1 predose and Day 14 ]
    To explore the potential of CYP3A4 interaction with GLPG2737



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male between 18-50 years of age, inclusive, on the date of signing the Informed Consent Form (ICF).
  2. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory tests prior to the initial study drug administration.

    Clinical safety laboratory test results must be within the laboratory reference ranges for males or test results that are outside the reference ranges for males need to be considered non clinically significant in the opinion of the investigator. One retest is allowed if deemed appropriate by the investigator.

  3. Liver function tests must meet the following criteria:

    1. aspartate aminotransferase (AST), ALT or alkaline phosphatase (ALP) <1.2x the upper limit of normal (ULN)
    2. Bilirubin not greater than ULN, however documented Gilbert's syndrome is acceptable. One retest is allowed if deemed appropriate by the investigator.
  4. Subject's screening ECG is considered normal or abnormal but clinically non-significant. QTcF must not exceed 450 msec. First degree heart block will not be considered as a significant abnormality.
  5. Forced expiratory volume in 1 second (FEV1) ≥ 80% of predicted normal for age, gender and height at screening.
  6. Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration.
  7. Negative drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) prior to dosing.
  8. Able and willing to comply with the prohibitions and restrictions as described in the protocol and with the contraceptive requirements as described in the protocol.
  9. Able and willing to sign the ICF as approved by the IEC, prior to any screening evaluations.

Exclusion Criteria:

  1. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
  2. Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or history of hepatitis from any cause with the exception of hepatitis A.
  3. History of or a current immunosuppressive condition (e.g., human immunodeficiency virus [HIV] infection type 1 and 2).
  4. Clinically significant illness in the 3 months before screening.
  5. Presence or having sequelae of gastrointestinal, liver (except for Gilbert's syndrome), kidney (creatinine clearance ≤ 80 mL/min using the Cockcroft-Gault formula: if calculated result ≤ 80 mL/min, a 24 hour urine collection to determine actual value can be done) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  6. History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated and with no evidence of recurrence).
  7. Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months of 5-half-lives of the drug (whichever is longer) before the initial drug administration.
  8. Active drug or alcohol abuse (an average intake of more than 21 glasses of wine or beer or equivalent/week) within 2 years prior to screening.
  9. Participation in a drug, drug/device or biologic investigational research study within 12 weeks or 5 half-lives of the investigational drug, if the half-life is known (whichever is longer) prior to screening.
  10. Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03410979


Locations
Layout table for location information
Netherlands
PRA-EDS
Groningen, Netherlands
Sponsors and Collaborators
Galapagos NV
Investigators
Layout table for investigator information
Study Director: Chris Brearley, BM, MRCP, MFPM Galapagos NV
Layout table for additonal information
Responsible Party: Galapagos NV
ClinicalTrials.gov Identifier: NCT03410979    
Other Study ID Numbers: GLPG2737-CL-101
2016-003626-17 ( EudraCT Number )
First Posted: January 25, 2018    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No